Hjem › Brystkreft › Texas › Fort Worth
Kliniske studier for Brystkreft i Fort Worth, TX
12 studier for Brystkreft søker deltakere på steder i og rundt Fort Worth (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Study of PHST001 in Advanced Solid Tumors
RekruttererFase 1
- START Center for Cancer Research - Texas, Fort Worth
IKS014 in Advanced Solid Tumors That Express HER2
RekruttererFase 1
- START Dallas - Fort Worth, Fort Worth
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
RekruttererFase 3
- JPS Health Network ( Site 0067), Fort Worth
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
RekruttererFase 3
- The Center for Cancer and Blood Disorders ( Site 0041), Fort Worth
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RekruttererFase 3
- JPS Oncology and Infusion Center ( Site 0083), Fort Worth
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
RekruttererFase 3
- JPS Health Network, Fort Worth
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
RekruttererFase 3
- JPS Health Network - Trinity Springs Pavilion, Fort Worth
- OneR The Center For Cancer And Blood Disorders (Texas Cancer Care), Fort Worth
- UT Southwestern Moncrief Cancer Institute, Fort Worth
- og 2 flere
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RekruttererFase 1
- Start - Dfw, Fort Worth
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
RekruttererFase 3
- Research Site, Fort Worth
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RekruttererFase 3
- JPS Health Network, Fort Worth
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekruttererFase 1/2
- USOR Texas Oncology, Fort Worth
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
RekruttererFase 3
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
Brystkreft-studier i andre byer
- New York City, NY136 studier
- Houston, TX126 studier
- Boston, MA112 studier
- Nashville, TN81 studier
- Los Angeles, CA73 studier
- Edison, NJ68 studier
- St. Louis, MO64 studier
- Queens, NY64 studier
- Durham, NC64 studier
- Chicago, IL59 studier
- Philadelphia, PA56 studier
- Dallas, TX55 studier
Andre studier i Fort Worth
- Ikke-småcellet lungekreft18 studier
- Eggstokkreft17 studier
- Endometriekreft12 studier
- Kreft (alle typer)9 studier
- Prostatakreft9 studier
- Tripelnegativ brystkreft7 studier
- Makuladegenerasjon7 studier
- Ulcerøs kolitt7 studier
- Nyrekreft (nyrecellekarcinom)7 studier
- Hjertesvikt7 studier
- Metastatisk kreft7 studier
- Kolorektal kreft7 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.